{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-23-000060","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.117938+00:00","generated_at":"2026-06-17T09:42:15.572287+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Centessa Q4 net loss $43.2M; cash $393.6M; SerpinPC, LB101, ORX750 progress","bullets":["Cash and cash equivalents $393.6M as of Dec 31, 2022; expected to fund operations into 2026.","Net loss attributable to ordinary shareholders $43.2M for Q4 2022 vs $60.8M in Q4 2021.","SerpinPC registrational program for hemophilia B ongoing; PRESent-5 enrolling; PRESent-2/3 dosing expected in 2023.","First subject dosed in Phase 1/2a trial of LB101 (PD-L1xCD47 LockBody) for solid tumors.","ORX750 nominated as product candidate for narcolepsy; preclinical data expected at scientific meeting in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-23-000060","json":"https://secwatch.observer/filing/0001847903-23-000060.json","markdown":"https://secwatch.observer/filing/0001847903-23-000060.md","text":"https://secwatch.observer/filing/0001847903-23-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000060/0001847903-23-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000060/cnta-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:42:15.572287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c22194c30713e0a946d2111aa70beaaf6ae3ecd5","claim":"Centessa Pharmaceuticals plc reported financial results for the fourth quarter and full-year ended December 31, 2022.","evidence_excerpt":"On March 30, 2023, Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000060/0001847903-23-000060-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full-year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}